Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/48913
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorALVES JUNIOR, Jose Mario-
dc.contributor.authorBERNARDO, Wanderley Marques-
dc.contributor.authorWARD, Laura Sterian-
dc.contributor.authorVILLAGELIN, Danilo-
dc.date.accessioned2022-08-12T17:21:56Z-
dc.date.available2022-08-12T17:21:56Z-
dc.date.issued2022-
dc.identifier.citationFRONTIERS IN ENDOCRINOLOGY, v.13, article ID 800257, 10p, 2022-
dc.identifier.issn1664-2392-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/48913-
dc.description.abstractContext: Although the overt hyperthyroidism treatment during pregnancy is mandatory, unfortunately, few studies have evaluated the impact of treatment on reducing maternal and fetal outcomes. Objective: This study aimed to demonstrate whether treatment to control hyperthyroidism manifested during pregnancy can potentially reduce maternal-fetal effects compared with euthyroid pregnancies through a systematic review with meta-analysis. Data Source: MEDLINE (PubMed), Embase, Cochrane Library Central, LILACS/BIREME until May 2021. Study Selection: Studies that compared, during the gestational period, treated women with hyperthyroidism versus euthyroid women. The following outcomes of this comparison were: pre-eclampsia, abruptio placentae, fetal growth retardation, gestational diabetes, postpartum hemorrhage, low birth weight, stillbirth, spontaneous abortions, premature birth. Data Extraction: Two independent reviewers extracted data and performed quality assessments. Dichotomous data were analyzed by calculating risk differences (DR) with fixed and random effect models according to the level of heterogeneity. Data Synthesis: Seven cohort studies were included. The results of the meta-analysis indicated that there was a lower incidence of preeclampsia (p=0.01), low birth weight (p=0.03), spontaneous abortion (p < 0.00001) and preterm birth (p=0.001) favouring the euthyroid pregnant group when compared to those who treated hyperthyroidism during pregnancy. However, no statistically significant differences were observed in the outcomes: abruptio placentae, fetal growth retardation, gestational diabetes mellitus, postpartum hemorrhage, and stillbirth. Conclusions: Our findings demonstrated that treating overt hyperthyroidism in pregnancy is mandatory and appears to reduce some potential maternal-fetal complications, despite there still being a residual risk of negative outcomes.eng
dc.language.isoeng-
dc.publisherFRONTIERS MEDIA SAeng
dc.relation.ispartofFrontiers in Endocrinology-
dc.rightsopenAccesseng
dc.subjecthyperthyroidismeng
dc.subjectpregnancyeng
dc.subjecttreatmenteng
dc.subjectmeta-analysiseng
dc.subjectmaternaleng
dc.subjectfetaleng
dc.subject.otheramerican thyroid associationeng
dc.subject.otherrisk-factorseng
dc.subject.othersubclinical hyperthyroidismeng
dc.subject.otherplacental abruptioneng
dc.subject.otherpreeclampsiaeng
dc.subject.othermanagementeng
dc.subject.othercohorteng
dc.subject.otherwomeneng
dc.subject.otherguidelineseng
dc.subject.otherdisorderseng
dc.titleEffect of Hyperthyroidism Control During Pregnancy on Maternal and Fetal Outcome: A Systematic Review and Meta-Analysiseng
dc.typearticleeng
dc.rights.holderCopyright FRONTIERS MEDIA SAeng
dc.identifier.doi10.3389/fendo.2022.800257-
dc.identifier.pmid35813653-
dc.subject.wosEndocrinology & Metabolismeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalALVES JUNIOR, Jose Mario:Univ Estadual Campinas, Postgrad Course Internal Med, Campinas, Brazil-
hcfmusp.author.externalWARD, Laura Sterian:Univ Estadual Campinas, Sch Med Sci, Lab Canc Mol Genet, Campinas, Brazil-
hcfmusp.author.externalVILLAGELIN, Danilo:Univ Estadual Campinas, Postgrad Course Internal Med, Campinas, Brazil; Univ Campinas PUC Campinas, Hosp Pontif Catholic, Endocrinol & Metab, Campinas, Brazil-
hcfmusp.description.articlenumber800257-
hcfmusp.description.volume13-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000827595100001-
hcfmusp.origem.id2-s2.0-85134013613-
hcfmusp.publisher.cityLAUSANNEeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAlexander EK, 2017, THYROID, V27, P315, DOI 10.1089/thy.2016.0457eng
hcfmusp.relation.referenceAndersen SL, 2014, EUR THYROID J, V3, P164, DOI 10.1159/000365101eng
hcfmusp.relation.reference[Anonymous], 1977, Acta Obstet Gynecol Scand, V56, P247eng
hcfmusp.relation.referenceBanhidy F, 2011, J MATERN-FETAL NEO M, V24, P305, DOI 10.3109/14767058.2010.487142eng
hcfmusp.relation.referenceBoisrame T, 2014, EUR J OBSTET GYN R B, V179, P100, DOI 10.1016/j.ejogrb.2014.05.026eng
hcfmusp.relation.referenceCasey BM, 2006, OBSTET GYNECOL, V107, P337, DOI 10.1097/01.AOG.0000197991.64246.9aeng
hcfmusp.relation.referenceCellini M, 2020, THYROID, V30, P457, DOI 10.1089/thy.2019.0456eng
hcfmusp.relation.referenceChu SY, 2007, DIABETES CARE, V30, P2070, DOI 10.2337/dc06-2559aeng
hcfmusp.relation.referenceDijkers M., 2013, KT UPDATE, V1, P1eng
hcfmusp.relation.referenceDownes KL, 2017, AM J PERINAT, V34, P935, DOI 10.1055/s-0037-1599149eng
hcfmusp.relation.referenceElbers LPB, 2018, J THROMB HAEMOST, V16, P634, DOI 10.1111/jth.13970eng
hcfmusp.relation.referenceFeki M, 2008, CLIN BIOCHEM, V41, P927, DOI 10.1016/j.clinbiochem.2008.05.002eng
hcfmusp.relation.referenceFerrero DM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162506eng
hcfmusp.relation.referenceHollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489eng
hcfmusp.relation.referenceKassebaum NJ, 2014, LANCET, V384, P980, DOI 10.1016/S0140-6736(14)60696-6eng
hcfmusp.relation.referenceKiserud T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002220eng
hcfmusp.relation.referenceKorevaar TIM, 2016, J CLIN ENDOCR METAB, V101, P5037, DOI 10.1210/jc.2016-2397eng
hcfmusp.relation.referenceLeger J, 2021, J CLIN ENDOCR METAB, V107, DOI [10.1210/clinem/dgab747, DOI 10.1210/CLINEM/DGAB747]eng
hcfmusp.relation.referenceLuewan S, 2011, ARCH GYNECOL OBSTET, V283, P243, DOI 10.1007/s00404-010-1362-zeng
hcfmusp.relation.referenceMannisto T, 2013, J CLIN ENDOCR METAB, V98, P2725, DOI 10.1210/jc.2012-4233eng
hcfmusp.relation.referenceMayrink J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46011-3eng
hcfmusp.relation.referenceMedici M, 2014, J CLIN ENDOCR METAB, V99, pE2591, DOI 10.1210/jc.2014-1505eng
hcfmusp.relation.referenceMestman, 1997, Medscape Womens Health, V2, P3eng
hcfmusp.relation.referenceMiyauchi S, 2013, ENDOCR J, V60, P449eng
hcfmusp.relation.referenceMoradinazar M, 2020, J PREGNANCY, V2020, DOI 10.1155/2020/4871494eng
hcfmusp.relation.referenceNangia AS, 2014, J OBSTET GYN INDIA, V64, P105, DOI 10.1007/s13224-013-0487-yeng
hcfmusp.relation.referenceNilsson SF, 2014, BJOG-INT J OBSTET GY, V121, P1375, DOI 10.1111/1471-0528.12694eng
hcfmusp.relation.referenceOhashi M, 2013, J PREGNANCY, V2013, DOI 10.1155/2013/619718eng
hcfmusp.relation.referencePage MJ, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n71eng
hcfmusp.relation.referencePhoojaroenchanachai M, 2001, CLIN ENDOCRINOL, V54, P365, DOI 10.1046/j.1365-2265.2001.01224.xeng
hcfmusp.relation.referencePillar N, 2010, INT J GYNECOL OBSTET, V108, P61, DOI 10.1016/j.ijgo.2009.08.006eng
hcfmusp.relation.referenceRoss DS, 2016, THYROID, V26, P1343, DOI 10.1089/thy.2016.0229eng
hcfmusp.relation.referenceSahu MT, 2010, ARCH GYNECOL OBSTET, V281, P215, DOI 10.1007/s00404-009-1105-1eng
hcfmusp.relation.referenceSaki F, 2014, INT J ENDOCRINOL MET, V12, DOI 10.5812/ijem.19378eng
hcfmusp.relation.referenceShahid MM, 2021, GYNECOL ENDOCRINOL, V37, P312, DOI 10.1080/09513590.2020.1866531eng
hcfmusp.relation.referenceSingh V, 2019, INT J REPROD CONTRAC, V8, P1594, DOI [10.18203/2320-1770.ijrcog20191224, DOI 10.18203/2320-1770.IJRCOG20191224]eng
hcfmusp.relation.referenceStagnaro-Green A, 2011, CLIN OBSTET GYNECOL, V54, P478, DOI 10.1097/GRF.0b013e3182272f32eng
hcfmusp.relation.referenceSu PY, 2011, J CLIN ENDOCR METAB, V96, P3234, DOI 10.1210/jc.2011-0274eng
hcfmusp.relation.referenceTaylor PN, 2018, NAT REV ENDOCRINOL, V14, P301, DOI 10.1038/nrendo.2018.18eng
hcfmusp.relation.referenceTurunen S, 2020, CLIN ENDOCRINOL, V93, P721, DOI 10.1111/cen.14282eng
hcfmusp.relation.referencevan Dijk MM, 2018, THYROID, V28, P257, DOI 10.1089/thy.2017.0413eng
hcfmusp.relation.referenceWells GA, 2009, NEWCASTLE OTTAWA SCAeng
hcfmusp.relation.referenceYang J, 2018, J TRACE ELEM MED BIO, V47, P104, DOI 10.1016/j.jtemb.2018.01.013eng
hcfmusp.relation.referenceYang YY, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.8401eng
hcfmusp.relation.referenceYou SH, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1845-7eng
hcfmusp.relation.referenceZhang YD, 2019, J WOMENS HEALTH, V28, P842, DOI 10.1089/jwh.2018.7180eng
dc.description.indexPubMedeng
hcfmusp.citation.scopus0-
hcfmusp.scopus.lastupdate2022-12-01-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/Outros
Outros institutos - HC/Outros

Artigos e Materiais de Revistas Científicas - LIM/47
LIM/47 - Laboratório de Hepatologia por Vírus

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_ALVES JUNIOR_Effect_of_Hyperthyroidism_Control_During_Pregnancy_on_Maternal_2022.PDFpublishedVersion (English)1.54 MBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.